Literature DB >> 30958693

Delta-like Protein 3 Prevalence in Small Cell Lung Cancer and DLL3 (SP347) Assay Characteristics.

Richard S P Huang1, Burton F Holmes1, Courtney Powell1, Raji V Marati1, Dusty Tyree1, Brittany Admire1, Ashley Streator1, Amy E Hanlon Newell1, Javier Perez1, Deepa Dalvi1, Ehab A ElGabry1.   

Abstract

CONTEXT.—: Delta-like protein 3 (DLL3) is a protein that is implicated in the Notch pathway. OBJECTIVE.—: To present data on DLL3 prevalence in small cell lung cancer and staining characteristics of the VENTANA DLL3 (SP347) Assay. In addition, the assay's immunoreactivity with other neoplastic and nonneoplastic tissues is outlined. DESIGN.—: Individual formalin-fixed, paraffin-embedded specimens of small cell lung cancer and tissue microarrays comprising neoplastic and nonneoplastic tissues were procured. Sections were cut and stained with DLL3 (SP347) assay. The slides were examined to determine prevalence, staining characteristics, and immunoreactivity. RESULTS.—: Cytoplasmic and/or membranous staining was observed in 1040 of 1362 specimens of small cell lung cancer (76.4%). Homogenous and/or heterogeneous and partial and/or circumferential granular staining with varied intensities was noted. Immunoreactivity was also observed in other neoplastic and nonneoplastic tissues. CONCLUSIONS.—: Our study findings provided the profile of DLL3 staining characteristics that can be used for determining the level of DLL3 expression in small cell lung cancer.

Entities:  

Year:  2019        PMID: 30958693     DOI: 10.5858/arpa.2018-0497-OA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  4 in total

1.  Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity.

Authors:  Kathryn M Tully; Salomon Tendler; Lukas M Carter; Sai Kiran Sharma; Zachary V Samuels; Komal Mandleywala; Joshua A Korsen; Avelyn Mae Delos Reyes; Alessandra Piersigilli; William D Travis; Triparna Sen; Nagavarakishore Pillarsetty; John T Poirier; Charles M Rudin; Jason S Lewis
Journal:  Clin Cancer Res       Date:  2022-04-01       Impact factor: 13.801

Review 2.  The Role of DLLs in Cancer: A Novel Therapeutic Target.

Authors:  Meng-Xi Xiu; Yuan-Meng Liu; Bo-Hai Kuang
Journal:  Onco Targets Ther       Date:  2020-05-07       Impact factor: 4.147

3.  Potential prognostic value of delta-like protein 3 in small cell lung cancer: a meta-analysis.

Authors:  Benchao Chen; Heng Li; Chao Liu; Shuting Wang; Feiyue Zhang; Li Zhang; Mingjie Li; Gaofeng Li
Journal:  World J Surg Oncol       Date:  2020-08-26       Impact factor: 2.754

4.  DLL3 (delta-like protein 3) expression correlates with stromal desmoplasia and lymph node metastases in medullary thyroid carcinomas.

Authors:  M Ingenwerth; T Brandenburg; D Führer-Sakel; M Goetz; F Weber; H Dralle; H-U Schildhaus; K W Schmid; S Theurer
Journal:  Endocr Connect       Date:  2021-03       Impact factor: 3.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.